Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-117 in Acute Myelogenous Leukemia
NCT03038230Phase 1Terminated
- Sponsor
- Merus
- Start
- Apr 2016
- Primary completion
- May 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of tepoditamab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Merus. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Apr 2016; status: terminated.
02
Drugs
tepoditamab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03038230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038230.